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Monica Charpentier5, Saranya Chumsri5,6, Massimo Cristofanilli7, Cha-Mei Tang8 and R. Katherine Alpaugh9
Abstract
Background: Enumeration of circulating tumor cells (CTCs) isolated from the peripheral blood of breast cancer
patients holds promise as a clinically relevant, minimally invasive diagnostic test. However, CTC utility has been
limited as a prognostic indicator of survival by the inability to stratify patients beyond general enumeration. In
comparison, histological biopsy examinations remain the standard method for confirming malignancy and grading
malignant cells, allowing for cancer identification and then assessing patient cohorts for prognostic and predictive
value. Typically, CTC identification relies on immunofluorescent staining assessed as absent/present, which is
somewhat subjective and limited in its ability to characterize these cells. In contrast, the physical features used in
histological cytology comprise the gold standard method used to identify and preliminarily characterize the cancer
cells. Here, we superimpose the methods, cytologically subtyping CTCs labeled with immunohistochemical
fluorescence stains to improve their prognostic value in relation to survival.
Methods: In this single-blind prospective pilot study, we tracked 36 patients with late-stage breast cancer over 24
months to compare overall survival between simple CTC enumeration and subtyping mitotic CTCs. A power
analysis (1-β = 0. 9, α = 0.05) determined that a pilot size of 30 patients was sufficient to stratify this patient cohort;
36 in total were enrolled.
Results: Our results confirmed that CTC number is a prognostic indicator of patient survival, with a hazard ratio 5.2,
p = 0.005 (95 % CI 1.6–16.5). However, by simply subtyping the same population based on CTCs in cytological
mitosis, the hazard ratio increased dramatically to 11.1, p < 0.001 (95 % CI 3.1–39.7).
Conclusions: Our data suggest that (1) mitotic CTCs are relativity common in aggressive late-stage breast cancer,
(2) mitotic CTCs may significantly correlate with shortened overall survival, and (3) larger and more defined patient
cohort studies are clearly called for based on this initial pilot study.
Keywords: Circulating tumor cells, Mitotic index of CTCs, Blood based biopsy, Breast cancer cell motility
Background
Using circulating tumor cells (CTCs) in patient stratifi-
cation has served as a noninvasive blood biomarker for
prognosis and response to therapy in late-stage cancer,
though the actual utility of CTCs remains largely aca-
demic [1, 2]. A primary reason for limited clinical use of
CTCs is the inability to translate prognostic applications
into mainstream clinical treatment [1, 2]. This is due to a
variety of reasons, including CTC rarity and the current
inability to accurately distinguish highly aggressive from
less aggressive cells [2–4]. In comparison, pathological
grading for cell differentiation, including assessing the
mitotic index (MI) in tumor tissue biopsies, is the gold
standard in cancer diagnosis, prognosis, and treatment
and is an intricate part of tumor-staging algorithms
[1, 5–9]. We hypothesized that, like tissue biopsies,
the inclusion of a mitotic cell count along with the
standard CTC enumeration may identify more aggressive
CTC populations and provide a more accurate prognostic
stratification of patients with breast cancer.
Cancer is graded by histopathological examination of a
tissue biopsy extracted from suspicious tissue samples,
primarily for cancer diagnosis [1, 5–9]. Histopathological
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examination also allows for stratification of patients
based on the morphology of the cells from the tissue
(i.e., cell grade) for aiding patient assessment and treat-
ment [1, 5–8]. Though many cancers are graded using
differing grading systems (e.g., Gleason, Bloom and
Richardson Nottingham) and there are issues with sub-
jectivity and tumor heterogeneity, certain aspects are
universal in the pathological assessment of malignancy
(i.e., MI and cell differentiation) [1, 5–9]. Mitosis in
tumor cell grading, identified by specific cellular events
occurring during cell division (e.g., prophase, metaphase,
anaphase, telophase [5, 9, 10]), is considered a primary
predictor of survival and an indicator of therapy re-
sponse [5–10].
In CTCs, the inability to provide detailed cytological
assessment in cells has led some groups to rely on the
related [11, 12], yet biologically independent [13, 14],
proliferation index (PI) in their quantification (i.e.,
methylation-inhibited binding protein 1 (clone MIB-1),
proliferating cell nuclear antigen (PCNA), Ki-67, etc.).
However, the use of PI biomarkers in cancer is highly
contested and controversial, and the quantification and
prognostic value of these markers is different to those of
mitosis [13, 14]. Given that there has been at least one
case study describing the visualization of mitosis in
CTCs [15], we wished to examine whether the more
basic visual cytological assessment of cells in mitosis is
applicable to CTCs and whether this information gives
similar clinical information to standard pathological as-
sessment [11–16].
CTCs are found in approximately 65–85 % of patients
with metastatic disease, and CTC enumeration is an inde-
pendent prognostic indicator of survival (i.e., high number
of CTCs equates to shorter survival) [2–4, 17–20]. As can-
cer grading is a form of morphological classification, it has
been suggested that characterizing additional CTC pheno-
types may provide additional prognostic stratification in
patients with cancer [3, 21–23]. Recently, we have shown
that filter-based isolation of CTCs from peripheral blood
retains detailed cellular architecture, allowing for a more
descriptive assessment of CTCs (i.e., apoptotic CTCs
and dividing CTCs) [3, 17, 18, 24]. Classification of
filtered tumor cells is currently used by histopatholo-
gists to identify and grade cancer cells from a number
of body fluids including urine (bladder) [10], lung aspi-
rates (lung) [25], and cerebral spinal fluid (brain/neuron)
[26], though it is not commonly used for blood-based
biopsies [3].
In this prospective pilot study, we examined the
morphology of CTCs in the peripheral blood of patients
with metastatic breast cancer (n = 36), and evaluated the
mitotic status of each cell to assess the prognostic value
of enumerated CTCs and their mitotic indices. These
data suggest that applying histology-based mitotic indices
to CTCs enhances patient stratification, and may provide
an improvement in their prognostic significance.
Methods
Blood sample collection
In total, whole peripheral blood samples were drawn
prospectively from 36 women who were actively under-
going treatment for previously confirmed stage III or
stage IV breast cancer, at either the Fox Chase Cancer
Center (FCCC) or University of Maryland, Baltimore
(UMB) between 2011 and 2013. The study group charac-
teristics can be found in Additional file 1: Table S1.
Anonymized peripheral blood samples were supplied
through a collaboration agreement with FCCC and
UMB, with written informed consent and according to
the local Institutional Review Board (IRB) approval at
Fox Chase Cancer Center or University of Maryland
Baltimore. In addition, healthy female volunteers (n = 16;
median age 52 years), donated blood samples with
written informed consent and approval from Western
Institutional Review Board. All anonymized blood
samples were drawn into CellSave preservative tubes™
(approximately 9 mL; Janssen Diagnostics): 7.5 mL of
blood was used to enumerate CTCs using CellSieve™
microfiltration at UMB, FCCC or Creatv Microtech. Re-
sults and patient identification from institutions were
not shared or communicated until completion of study.
CellSieve™ low-flow microfiltration procedure
Samples were run at FCCC, UMB or Creatv Microtech
with a CellSieve™ Microfiltration Assay using a low-
pressure vacuum system [18]. CellSieve™ Microfiltration
Assay isolates CTCs based on size exclusion >7 μm, then
a trained cytologist identifies CTCs based on the mor-
phological features and the phenotypic expression of
EpCAM, Cytokeratins 8, 18, and 19, and 4',6-diamidino-
2-phenylindole (DAPI) (Fig. 1 and Additional file 1:
Figures S1 and S2 (Additional file 1 is available in the
online version of this paper)). Briefly, a low-pressure
vacuum with CellSieve™ microfilters on a filter holder
assembly is placed onto a waste apparatus. Whole
peripheral blood (7.5 mL) collected in CellSave pre-
servative tubes™ is prefixed, drawn through the filter
(approximately 3 minutes), washed with PBS, post-fixed,
and permeabilized. The filter is stained with an antibody
cocktail of FITC-anti-Cytokeratin 8, 18, and 19; Phyco-
erythrin (PE)-EpCAM; and Cy5-CD45 [3, 17, 18]. Filters
are washed and slide mounted with Fluoromount-G/
DAPI (Southern Biotech). Pathologically definable CTCs
(PDCTCs) are morphologically identified using pre-
established cytological features as previously described [3].
An Olympus BX54WI fluorescent microscope with Carl
Zeiss AxioCam and Zen2011 Blue (Carl Zeiss) was used
to image cells.
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Enumerating CTCs
We have previously defined the various CTC subtypes
isolated from patients with breast cancer. For this study,
only intact cells that have pathologically definable char-
acteristics (PDCTCs), as previously described [3], were
counted as CTCs in this study. This includes CTCs that
are CD45-negative, have a strong filamentous cytokera-
tin signal and have DAPI-positive nuclei with malignant
pathological criteria. PDCTCs were identified and im-
aged by a trained cytologist and confirmed by a patholo-
gist [3]. Apoptotic CTCs, CTCs undergoing epithelial to
mesenchymal transition (i.e., absence of cytokeratin),
and CTCs that could not be cytologically identified as
malignant were not included in this study [3, 24].
Grading mitotic proliferation
Mitosis was identified by a trained cytologist and con-
firmed by a pathologist. The stages of active mitosis, in-
cluding prophase, prometaphase, metaphase, anaphase,
telophase and cytokinesis, are all well-described using
both nuclear and cytokeratin structures [5–8]. CTCs
were only counted as mitotic if the cytologist could
identify the cell was in a stage of M phase, otherwise the
CTC was counted as non-mitotic (Additional file 1:
Figures S1 and S2).
Statistical methods
Kaplan-Meier estimates and Cox proportional hazard re-
gression analyses were performed in Matlab R2013A
using the enumerated CTC counts from all subtypes and
the known patient populations. For survival analysis, the
time to death was defined as the interval between when
blood sample was obtained until death, or censored by
last follow up visit. Estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor
receptor-2 (HER2) status were determined according to
local guidelines. HER2 was considered positive at a value
equal to or greater than 2+ (Additional file 1: Figure S3
and Additional file 1: Table S1). Cancer subtype, hor-
mone status and stage were determined at the time
blood was obtained. A power analysis (1-β = 0. 9, α = 0.05)
Fig. 1 Common cytology of circulating tumor cells (CTCs) in mitosis,
isolated from patients with breast cancer. Representative images
of a the “classical” CTC in interphase (the most commonly found
morphology), b prophase CTC with condensing chromatin,
c metaphase CTC with condensed chromatin lining up along the
axis, d metaphase/anaphase where two chromatins are separating
along the cell plate, e anaphase where two chromosome sets are
moving to cell poles, f telophase showing two cell envelopes and a
contractile ring at the center of the cell, g cytokinesis showing the
contractile ring pinching the cell into two, and h late cytokinesis
during which the nuclear envelopes are reformed, contractile ring
almost complete and chromatin has expanded. Blue 4',6-diamidino-2-
phenylindole-positive nuclei, green cytokeratin. Scale bar 15 μm
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determined that a sample size of 30 patients was sufficient
to stratify patient cohorts based on previous CTC data
analysis [3].
Results
CTCs were found in 83 % of patient samples and in none
of the healthy control samples, consistent with published
studies (i.e., CellSearch® identifies CTCs in approximately
65–80 % of late-stage breast cancer) [1, 2, 4, 19, 20]. The
majority of CTCs (approximately 91 %), identified by the
differential staining of cytokeratin-positive, DAPI-positive
and CD45-negative, had a malignant appearance, i.e., high
cytoplasmic to nuclear ratios, high pleomorphism, and
well-structured filamentous cytokeratin (Fig. 1, Additional
file 1: Figures S1 and S2) [3, 4, 17–20].
We divided the patient cohort into subsets using the
standard clinical cut off of ≥5 CTCs/sample to deter-
mine patient survival [1–4, 17–20]. Specifically, 23 of 36
patients (64 %) had <5 CTCs, with a median survival
of >24 months, whereas 13 of 36 patients (36 %) had ≥5
CTCs, with a median survival of 10.0 months, hazard ratio
5.2 (Fig. 2a and Table 1). This hazard ratio was within the
confidence interval of published ratios establishing ≥5
CTCs as the optimal cut off for evaluating patients (i.e.,
26–49 % of patients with late-stage breast cancer have ≥5
CTCs per sample with reported median survival ranging
from 10.1 to 15.0 months [1–4, 17–20]).
All CTCs were then sub-classified based on the
cytological identification of M phase phenotypes [1–4,
17–20, 27]. We identified CTCs in all stages of mitosis
from the patient cohort (Fig. 1b-h) [5, 6, 8, 27]. Specific-
ally, 23 of 36 patients (64 %) had no mitotic CTCs, with
a median survival >24 months, whereas 13 of 36 patients
(36 %) had ≥1 mitotic events, with a median survival of
5.7 months, hazard ratio 11.1 (Fig. 2b, Table 1 and
Additional file 1: Figure S4). Of note, mitotic events
were detected in four patients with <5 CTCs and were
not detected in four patients with ≥5 CTCs (Additional
file 1: Figures S4 and S5). These data suggest that the
additional visual characterization of mitosis in CTCs
enhances the stratification of patients with breast cancer
for prognostic correlation with survival, compared with
CTC enumeration alone. In the re-stratified cohort,
92 % of patients with at least one mitotic CTC died
within the 2-year period of observation vs 13 % of
patients without mitotic CTCs, representing an 11-
fold increase in patient risk (Table 1 and Fig. 2).
Of the 155 mitotic events identified, prophase was the
most commonly observed (78 % of mitotic CTCs, or 121
cells), followed by telophase/cytokinesis (15 %, or 23
cells). Metaphase and anaphase were rarely observed,
with only 4 in anaphase and 6 in metaphase, 2.6 % and
3.9 %, respectively. Interestingly, the frequency of mitotic
events was more common than expected, at 9.3 % of all
CTCs.
Discussion
For many years, CTC research has attempted to differ-
entiate clinically relevant CTCs from CTCs playing no
role in metastatic spread, by analyzing mutation rates,
proteomes, epithelial-to-mesenchymal transition, etc.
[2, 17, 19, 20, 28], to improve their clinical utility.
While it has been established that enumerating CTCs
using the threshold of ≥5 CTC per sample is prog-
nostically valuable, translating this information into
direct treatment for improved patient survival has
been difficult [1, 2, 12, 28]. Recently, protein level
and genomic phenotyping of single CTCs has shown
that they are a heterogeneous population of multiple
complicated phenotypes [22, 28–30] and subtyping
CTCs by this biomarker heterogeneity is an ongoing
area of study. However, the complex heterogeneity,
Fig. 2 Kaplan-Meier estimates of probabilities of overall survival in the breast cancer patient populations, total circulating tumor cell (CTC) count
versus mitotic CTC count (n = 36). a Kaplan-Meier estimates of probabilities of overall survival of patients with breast cancer with <5 CTCs per
sample vs patients with ≥5 CTCs per sample. b Kaplan-Meier estimates of probabilities of overall survival of patients with breast cancer with 0 mitotic
CTCs per sample vs patients with ≥1 mitotic CTCs per sample
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low numbers of CTC per sample, and the fact that
20–35 % of patients with late-stage cancer have no
measurable CTCs, are all confounding factors inhibit-
ing clinical utility [1, 2, 4, 12, 19]. In contrast to pro-
filing CTCs with additional proteomic biomarkers, we
analyzed cells using a more basic scientific approach,
by identifying the cancer phenotype known to correl-
ate with highly aggressive malignancies, i.e., mitosis,
and known to provide predictive information about
therapeutic response [5–9]. Using a sample size suffi-
cient to properly stratify this patient cohort, our re-
sults determined that while CTC number is in fact a
prognostic indicator of patient survival, by simply
subtyping the same population based on CTCs in
cytological mitosis, the hazard increased dramatically
to 11.1. By identifying this highly aggressive CTC
phenotype, we may now attempt to better understand
these CTCs using more sophisticated molecular and
proteomic targeting techniques, profiling these cells
for mutations, stem cell properties, etc.
Using cytological assessment of CTCs, combined
with the calculated patient survival, these observations
imply that there are quantifiable populations of intact
CTCs in mitosis found outside the tumor area, which
could be the sought after clinically relevant CTC pop-
ulations. While it cannot be determined whether
these CTCs are actively dividing in the circulation or
that dividing CTCs are simply breaking off the tumor
into the circulatory system, the finding of these cells
in late-stage breast cancer is intriguing. Considering
that mitotic cells are less stable and prone to struc-
tural collapse, the stress of circulation should intui-
tively lessen the frequency of mitotic CTCs and
destroy the cells before isolation, which did not occur
[5–8]. Biologically, these events hint at aggressive cel-
lular subtypes involved in the metastatic cascade, and
our observations imply that there are quantifiable
populations of CTCs in the mitotic phase found out-
side the tumor area.
Despite being a small cohort, the patient population
represented patients with a heterogeneous group of
breast cancers with a diverse hormone status (Table 1,
Fig. 2 and Additional file 1: Table S1) and distinct cohort
separation, indicating the possible applications to breast
cancer in general. While these observations must now
be expanded to include a larger and more diverse popu-
lation of cancer patients, the sample size used in this
study is more than sufficient to justify further testing for
this CTC subtype in patients with late-stage breast can-
cer (Fig. 2 and Table 1). The presence of mitotic CTCs,
and the association with increased risk, indicates the ex-
istence of a statistically significant cohort with an ag-
gressive cancer subtype, dictating the need to further
research this biological event and expand this study to a
larger group of women.
Conclusion
We suggest that tracking these mitotic cancer cells tran-
siting the circulatory system provides a simple noninva-
sive method to gather clinical information on highly
aggressive tumor cells and possibly aid the planning of
patient treatment as tumor progression evolves. While
tumor “omics” profiling promises a future of personal-
ized treatment, the spread of disease (i.e., stage) followed
by the aggressiveness of disease (i.e., grade) currently
remain the first and second most important factors in a
patient’s survival and treatment. Here, we suggest that
incorporating mitotic indices into CTC assessment
might better stratify patients into prognostic groups, bet-
ter inform a physician of tumor evolution, and identify
the more aggressive cancer targets using a blood-based
biopsy.
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Additional file 1: Figure S1. Common recognizable Cytologies of CTCs
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in Mitosis isolated from breast cancer patients with all the “standard” CTC
stains from Fig. 1. Figure S3. Kaplan-Meier estimates of probabilities of
Overall Survival of the patient subpopulations based on receptor status
from Fig. 2a (n=33). Figure S4. Box plot of total number of CTCs in each
patient versus mitotic CTCs for each patient. Figure S5. CTC counts and
Mitotic CTC counts for each patient sample in relation to time of filtration
after blood draw. Table S1. Patient subpopulations classified by stage,
receptor status and treatment. (PDF 748 kb)
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Table 1 Prediction table with the hazard ratios, confidence
intervals and p values for the patient populations (n = 36)
Variable Hazard
ratio
95 % CI P value
1 mitotic CTC vs 0 mitotic CTC 11.1 3.1-39.7 <0.001
≥5 CTC vs <5 CTC 5.2 1.6-16.5 0.005
1 mitotic CTC or ≥5 CTCs vs 0 mitotic CTCs
and <5 CTCs
8.0 1.8-35.4 0.006
ER/PR-positive vs ER/PR-negative 1.3 0.5-3.7 0.174
HER2-positive vs HER2-negative 1.8 0.6-5.7 0.289
Hormone-positive vs hormone-negative (tn) 4.0 1.4-11.2 0.009
CTC circulating tumor cell, ER estrogen receptor, PR progesterone receptor,
HER2 human epidermal growth factor receptor-2, Tn triple negative
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